Interaction Between Decidual Cells and NK Cells in Endometriosis (NCT07652593) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Interaction Between Decidual Cells and NK Cells in Endometriosis
France50 participantsStarted 2026-06
Plain-language summary
Endometriosis is a chronic gynecological disease characterized by the presence of endometrial-like tissue outside the uterus and is frequently associated with pelvic pain and infertility. Increasing evidence suggests that immune dysfunction may contribute to the development and persistence of the disease.
The purpose of this prospective case-control study is to compare immune cell characteristics in women with deep endometriosis and women without endometriosis during the secretory phase of the menstrual cycle. Participants will undergo collection of clinical data, blood samples, endometrial samples, and vaginal microbiota samples. For participants undergoing clinically indicated pelvic surgery, additional biological samples may be collected during the procedure. The study aims to improve understanding of the immune mechanisms involved in endometriosis and to identify potential biomarkers associated with the disease.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Endometriosis Group
* Female participant aged 18 years or older.
* Confirmed diagnosis of deep endometriosis by imaging or surgery.
* Pelvic pain and/or severe dysmenorrhea (Visual Analog Scale \> 4).
* Premenopausal.
* No contraceptive or hormonal treatment during the study menstrual cycle.
* Affiliated with a health insurance system.
* Able and willing to provide written informed consent.
* Control Group
* Female participant aged 18 years or older.
* No diagnosis of endometriosis.
* Premenopausal.
* No contraceptive or hormonal treatment during the study menstrual cycle.
* No chronic pelvic pain or severe dysmenorrhea (Visual Analog Scale \< 4).
* Affiliated with a health insurance system.
* Able and willing to provide written informed consent.
Exclusion Criteria:
* Current infection.
* Active cancer.
* Active autoimmune disease.
* Concomitant hormonal treatment.
* Pregnancy.
* Participant under guardianship or legal protection.
* Participant deprived of liberty.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
CD39 Expression on Natural Killer Cells in Endometrial and Peritoneal Samples
Timeframe: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)